First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Authors :: Moore, Kathleen N.
Bouberhan, Sara
Hamilton, Erika P.
Liu, Joyce F.
O'Cearbhaill, Roisin Eilish
O'Malley, David M.
Papadamitriou, Konstantinos
Schröder, David
Van Nieuwenhuysen, Els
Yoo, Suk-Young
Peterman, Mary Jane
Goncalves, Priscila Hermont
Schmidt, Tamara
Zhu, Min
Lowy, Israel
Uldrick, Thomas S.
Miller, Elizabeth
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS5624-TPS5624, 1p
Publication Year :: 2023

Full Text Access

Tools